Tempest Therapeutics Inc
TPST7.330USD
-0.160-2.14%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.98MCap. mercado
PérdidaP/E TTM
Más Datos de Tempest Therapeutics Inc Compañía
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Información de la empresa
Símbolo de cotizaciónTPST
Nombre de la empresaTempest Therapeutics Inc
Fecha de salida a bolsaOct 04, 2012
Director ejecutivo- -
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 04
Dirección2000 Sierra Point Parkway
CiudadBRISBANE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94005
Teléfono14157988589
Sitio Webhttps://www.tempesttx.com/
Símbolo de cotizaciónTPST
Fecha de salida a bolsaOct 04, 2012
Director ejecutivo- -
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 24 de jul
Actualizado: jue., 24 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Versant Ventures
6.87%
BlackRock Institutional Trust Company, N.A.
1.09%
Geode Capital Management, L.L.C.
0.85%
Fidelity Management & Research Company LLC
0.85%
UBS Financial Services, Inc.
0.63%
Other
89.70%
Accionistas
Accionistas
Proporción
Versant Ventures
6.87%
BlackRock Institutional Trust Company, N.A.
1.09%
Geode Capital Management, L.L.C.
0.85%
Fidelity Management & Research Company LLC
0.85%
UBS Financial Services, Inc.
0.63%
Other
89.70%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
6.87%
Investment Advisor
3.49%
Investment Advisor/Hedge Fund
1.15%
Individual Investor
0.14%
Research Firm
0.08%
Bank and Trust
0.04%
Other
88.22%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
71
462.31K
11.78%
-320.03K
2025Q1
72
466.15K
11.99%
-315.34K
2024Q4
74
6.85M
15.70%
-2.07M
2024Q3
64
6.40M
25.40%
-2.51M
2024Q2
60
6.46M
29.08%
-2.26M
2024Q1
57
6.17M
27.79%
-2.56M
2023Q4
58
6.52M
33.89%
-1.52M
2023Q3
54
8.53M
66.99%
-219.33K
2023Q2
55
8.95M
101.95%
+3.83M
2023Q1
67
8.34M
99.34%
+3.30M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Versant Ventures
269.77K
6.87%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
42.91K
1.09%
+742.00
+1.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
33.33K
0.85%
+6.08K
+22.32%
Mar 31, 2025
Fidelity Management & Research Company LLC
33.23K
0.85%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
24.90K
0.63%
+11.25K
+82.43%
Mar 31, 2025
The Vanguard Group, Inc.
22.91K
0.58%
+9.36K
+69.07%
Mar 31, 2025
Susquehanna International Group, LLP
8.81K
0.22%
-682.00
-7.18%
Mar 31, 2025
Northern Trust Investments, Inc.
7.64K
0.19%
+2.43K
+46.54%
Mar 31, 2025
Brady (Stephen R)
3.61K
0.09%
+46.00
+1.29%
Apr 09, 2025
State Street Global Advisors (US)
3.19K
0.08%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Fecha
Tipo
Relación
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
